Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 4 days ago

CRESCENT BIOPHARMA, INC.: BALYASNY ASSET MANAGEMENT L.P. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Balyasny Asset Management L.P. amended its Schedule 13G stake filing for Crescent Biopharma, Inc., disclosing the change to the SEC under accession number 0001172661-26-005039. The filing updates the asset manager's previously reported beneficial ownership position in the biopharma company. Schedule 13G amendments are typically filed when a passive investor's stake crosses or moves past the 5% reporting threshold or when previously reported holdings change materially. The exact revised share count and ownership percentage were not detailed in the filing headline, and investors will watch for the full amendment to gauge whether Balyasny's position increased or was trimmed.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Balyasny Asset Management L.P., Crescent Biopharma, Inc.